

University of Groningen

Urinary Calcium Is Associated with Serum Sclerostin among Stone Formers

Rodrigues, Fernanda Guedes; Ormanji, Milene Subtil; Pietrobon, Igor Gouveia; Matos, Ana Cristina Carvalho de; De Borst, Martin H.; Heilberg, Ita Pfeferman

Published in:
Journal of Clinical Medicine

DOI:
[10.3390/jcm12155027](https://doi.org/10.3390/jcm12155027)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2023

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Rodrigues, F. G., Ormanji, M. S., Pietrobon, I. G., Matos, A. C. C. D., De Borst, M. H., & Heilberg, I. P. (2023). Urinary Calcium Is Associated with Serum Sclerostin among Stone Formers. *Journal of Clinical Medicine*, 12(15), Article 5027. <https://doi.org/10.3390/jcm12155027>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.


Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Article

Urinary Calcium Is Associated with Serum Sclerostin among Stone Formers

Fernanda Guedes Rodrigues^{1,2,*}, Milene Subtil Ormanji³, Igor Gouveia Pietroboim³,
Ana Cristina Carvalho de Matos³, Martin H. De Borst²  and Ita Pfeferman Heilberg^{1,3} 

¹ Nutrition Post Graduation Program, Universidade Federal de São Paulo, São Paulo 04023-062, Brazil; ita.heilberg@gmail.com

² Department of Nephrology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands; m.h.de.borst@umcg.nl

³ Division of Nephrology, Universidade Federal de São Paulo, São Paulo 04023-062, Brazil; milene.ormanji@gmail.com (M.S.O.); igorpietroboim@gmail.com (I.G.P.); anacrismatos21@gmail.com (A.C.C.d.M.)

* Correspondence: f.guedes.rodrigues@umcg.nl

Abstract: Background: Sclerostin plays an important role in bone metabolism and adipose tissue. Animal studies suggest that sclerostin influences urinary calcium (UCa), but this relationship has not been evaluated in stone formers (SFs). We aimed to investigate the association of UCa with serum sclerostin, bone mineral density (BMD), and body composition among SFs. Methods: Clinical and laboratorial data were retrieved from medical records. Determinants of UCa were studied using linear regression. Results: A total of 107 SFs (35.8 ± 9.3 years, 54% male) with eGFR 99.8 ± 14.5 mL/min/1.73 were studied. Subjects were split by sex and grouped into tertiles of UCa levels. Men in the highest UCa tertile had higher body mass index (BMI) and serum sclerostin, lower lean mass, and a trend towards higher fat mass. Women in the highest tertile had higher BMI and a trend towards higher serum sclerostin. Hypertension and metabolic syndrome, but not lower BMD, were more prevalent in the highest UCa tertile for both sexes. Sclerostin was positively correlated with fat mass and inversely correlated with lean mass among men, but not among women. BMD corrected for BMI at lumbar spine was inversely associated with UCa in a univariate analysis, but only serum sclerostin, hypertension, and NaCl intake were independent determinants of UCa in the multivariate model. Conclusion: The present findings disclose that in addition to hypertension and salt intake, serum sclerostin is associated with urinary calcium in stone formers, suggesting that in addition to the hormones traditionally thought to alter calcium reabsorption in the kidney, sclerostin may play a significant additional role, warranting further investigation.

Keywords: kidney stones; urinary calcium; serum sclerostin; bone mineral density



Citation: Rodrigues, F.G.; Ormanji, M.S.; Pietroboim, I.G.; Matos, A.C.C.d.; De Borst, M.H.; Heilberg, I.P. Urinary Calcium Is Associated with Serum Sclerostin among Stone Formers. *J. Clin. Med.* **2023**, *12*, 5027. <https://doi.org/10.3390/jcm12155027>

Academic Editor: Jonathan Barratt

Received: 26 June 2023

Revised: 24 July 2023

Accepted: 28 July 2023

Published: 31 July 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Background

Hypercalciuria is the most common metabolic abnormality found in nearly 50% of calcium stone formers and characterized as a systemic abnormality of calcium homeostasis in which a dysregulation of calcium transport takes place in the kidneys, intestine, and bones, under influence of genetics, diet, and hormones, such as parathyroid hormone (PTH), fibroblast growth factor-23 (FGF-23), and the active form of vitamin D₃, 1,25-dihydroxyvitamin-D₃ (1,25(OH)₂D₃) [1–3].

Increased body mass index (BMI) has been associated with alterations in urinary composition, including enhanced urinary calcium excretion [4]. A previous study of our group in stone-forming patients has disclosed a positive correlation of urinary calcium excretion not only with BMI, but also with waist circumference [5], suggesting an effect of body composition on calciuria.

Stone formers (SFs) exhibit reduced bone mineral density (BMD) [6,7], and previous histomorphometric studies have evidenced low bone formation and increased bone resorption [8,9]. Although bone demineralization occurs mostly in SFs with idiopathic hypercalciuria [8–10], it may be detected in normocalciuric SFs as well [11,12].

Sclerostin, a glycoprotein expressed by osteocytes as an inhibitor of the Wnt- β catenin pathway, is a negative regulator of bone formation [13], and its circulating levels exhibit a positive association with BMI and fat mass in healthy subjects [14,15]. It follows that *Sost* gene (which encodes sclerostin) knockout (KO) mice have reduced fat mass and adipocyte size [16] as well as increased BMD due to greater bone formation [17]. Interestingly, another experimental study showed that mice with sclerostin gene deletion exhibited a reduction in urinary calcium levels [18]. To date, little is known about the effects of circulating sclerostin upon urinary calcium among SFs. Therefore, we aimed to characterize a possible relationship of urinary calcium levels with circulating sclerostin, BMD, and body composition in this population.

2. Methods

2.1. Study Population

Adult stone-forming patients, referred to the Nephrolithiasis Outpatient Clinic of the Universidade Federal de São Paulo (UNIFESP) because of an established diagnosis of renal stone, were enrolled in the present retrospective study with cross-sectional analysis. A diagnosis of nephrolithiasis was made based on the presence of renal colic with hematuria, spontaneous calculi voiding, and/or surgical/endoscopic removal of the stones and/or radiographic evidence of stone(s).

The present study is based on available data retrieved from their medical records regarding clinical characteristics, nutritional and biochemistry data, as well as bone mineral density (BMD) and body composition determined by dual energy X-ray absorptiometry (DXA). Patients had DXA and biobank available due to participation in a previous study. Metabolic syndrome was diagnosed according to the American Heart Association criteria. Serum levels of sclerostin, 1,25 dihydroxyvitamin D₃ (1,25(OH)₂D₃), fibroblast growth factor 23 (FGF-23), and klotho were presently measured in their stored blood samples whenever available.

Exclusion criteria were men over 60 years old, postmenopausal women, estimated glomerular filtration rate (eGFR) by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation < 90 mL/min/1.73 m², diabetes mellitus, renal tubular acidosis, hyperparathyroidism, or past use of thiazides, corticosteroids, and anticonvulsants.

Written consent was obtained from each patient, and the study protocol was approved by the local Medical Ethics and Research Committee of UNIFESP (number 4.869.310) in accordance with the Helsinki Declaration of 1975.

2.2. Bone Mineral Density and Body Composition

Bone densitometry was assessed by DXA (QDR 4500, Hologic Inc., Waltham, MA, USA) with measurements of BMD at lumbar spine, femoral neck, and total femur. Fat mass and lean mass were also determined by DXA, and the percentage of both was calculated by total body weight. Anthropometric parameters (weight and standing height) were used to calculate body mass index (BMI). To correct for the influence of the weight load on bone, the lumbar spine, femoral neck, and total femur were also expressed as a ratio corrected for BMI (BMD/BMI) [19].

2.3. Nutritional Data

Micronutrients intake, such as calcium, phosphorus, and potassium, was obtained by a 3-day food-intake record under unrestricted diet, and their daily consumption was adjusted for the total energy intake and calculated using the Dietpro—version 6.0 software (USDA nutrients data). Sodium chloride (NaCl) intake was estimated from 24 h urine sodium excretion and the protein intake from 24 h urea excretion using the protein equivalent of

nitrogen appearance (PNA) formula. $PNA = (\text{urinary urea nitrogen} + [0.031 \times \text{weight (kg)}]) \times 6.25$, where urinary urea nitrogen is $(\text{urinary urea (mg/L/24 h)}/2.14 \times \text{urinary volume in 24 h (L)})$.

2.4. Biochemical Parameters

The serum parameters analyzed in stored blood samples were sclerostin, $1,25(\text{OH})_2\text{D}_3$, FGF-23, and klotho. The 24-hr urinary biochemistry (calcium, oxalate, phosphate, sodium, potassium and urea) and the remaining serum biochemical and hormonal parameters (creatinine, $25(\text{OH})\text{D}_3$, PTH, and bone alkaline phosphatase (BAP)) were obtained from their medical records. Serum $25(\text{OH})\text{D}_3$, $1,25(\text{OH})_2\text{D}_3$, and PTH were determined by a chemiluminescence assay (Architect i200 SR, Abbott). Serum FGF-23, Klotho, sclerostin, and BAP were quantified using ELISA kits (Immutopics Inc., USA; IBL, USA; Teco Medical, Sissach, Switzerland; Quidel, San Diego, CA, USA; respectively). Urinary oxalate was determined via an enzymatic method (Trinity Biotech, Bray, Ireland). Urinary and serum creatinine was determined according to the modified Jaffe's reaction. Urinary calcium and phosphate were determined by a colorimetric method and sodium and potassium by an ion-selective electrode. All biochemical parameters were measured in a Beckman Clinical Chemistry Analyzer (AU480- Beckman Coulter, Brea, CA, USA). The eGFR was calculated using the 2022 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

2.5. Statistical Analysis

Statistical analyses were performed using IBM SPSS version 23.0 (SPSS Inc., Chicago, IL, USA). In all analyses, $p < 0.05$ was considered significant. Variable distribution was evaluated via the Kolmogorov–Smirnov test. Categorical variables are presented as n (%), normally distributed variables as mean \pm standard deviation (SD), and non-normally distributed variables as median (interquartile range). Comparison of categorical variables was performed using a Chi-square test. Differences in tertiles were tested through an analysis of variance (ANOVA) with the Bonferroni post hoc tests for normally distributed variables and the Kruskal–Wallis test for non-normal distribution. Possible determinants of urinary calcium were studied using univariate linear regression. Since we aimed to explore the potential relevance of clinical and nutritional factors as potential determinants, we tested all variables of known clinical importance for urinary calcium (i.e., body composition, dietary sodium and protein, presence of hypertension and metabolic syndrome, serum PTH and BAP, FGF-23, sclerostin, $1,25(\text{OH})_2\text{D}_3$, and $25(\text{OH})\text{D}_3$) in univariate regression analysis. Subsequently, all variables with a $p < 0.10$ were included in a multivariate linear regression model to identify the independent determinants of urinary calcium. Predictors were tested for collinearity using variance inflation factor analysis. Residuals were checked for normality and were natural log-transformed when appropriate. Co-adjustment for energy was performed for all nutrients using the residual method.

3. Results

Clinical characteristics and nutritional data of the participants included in the analyses are shown in Table 1. The subjects were divided by sex and clustered into three groups according to tertiles (T) of urinary calcium. Rationale for separating patients according to sex was the well-established differences in body composition and BMD for men and women. A total of 107 (one hundred and seven) SFs were included in the study with a mean age of 35.8 ± 9.3 years. There was no statistical difference regarding age and duration of disease across tertiles. Among men, means of BMI were higher in T3 when compared to T1 and T2, while the percentage of lean mass was higher in the former. Among women, T3 presented higher BMI when compared to T2. Among both sexes, there was a higher prevalence of hypertension and metabolic syndrome in T3 than T1 and T2. With respect to nutritional data, there were no differences between groups regarding intakes of protein, NaCl, calcium, phosphorus, and potassium among men. However, among women, T3 presented the higher intake of NaCl.

Table 1. Clinical characteristics and nutritional data of SFs clustered into tertiles according to urinary calcium.

	Men			Women		
	T1 n = 19 (≤180 mg/24 h)	T2 n = 20 (180.1–283.0 mg/24 h)	T3 n = 19 (≥283.1 mg/24 h)	T1 n = 16 (≤150 mg/24 h)	T2 n = 17 (150.1–289.0 mg/24 h)	T3 n = 16 (≥289.1 mg/24 h)
Age, years	35.2 ± 7.9	38.3 ± 9.8	38.0 ± 10.3	31.6 ± 9.3	33.8 ± 8.3	37.4 ± 9.2
Duration of disease, years	9.0 (4.0–14.0)	9.0 (1.3–14.0)	7.0 (1.0–17.0)	9.0 (2.3–13.5)	5.5 (1.3–13.8)	3.5 (2.0–20.0)
BMI (kg/m ²)	26.3 ± 4.8	26.6 ± 3.8	29.4 ± 4.3 ^{ab}	24.6 ± 2.5	26.4 ± 5.1	27.8 ± 5.3 ^a
Fat mass (%)	23.4 ± 7.3	22.6 ± 6.8	25.2 ± 5.4 ^c	33.7 ± 6.4	33.8 ± 7.4	36.0 ± 4.8
Lean mass (%)	73.7 ± 6.7	74.6 ± 6.9	71.8 ± 5.0 ^{ab}	63.7 ± 6.9	63.5 ± 7.3	61.4 ± 4.8
Hypertension, n (%)	0 (0)	3 (15.0) ^a	5 (26.3) ^a	1 (6.3)	1 (5.9)	6 (37.5) ^{ab}
Metabolic syndrome, n (%)	2 (10.5)	5 (25.0) ^a	8 (42.1) ^a	1 (6.3)	2 (11.8)	6 (37.5) ^{ab}
Nutritional data						
PNA (g/day)	1.0 ± 0.2	0.9 ± 0.4	1.1 ± 0.2	0.8 ± 0.5	1.0 ± 0.4	1.0 ± 0.4
NaCl (g/day)	12.9 ± 4.4	14.0 ± 5.6	15.5 ± 5.3	9.8 ± 4.2	10.5 ± 3.0	14.1 ± 4.5 ^{ab}
Energy-adjusted daily intake						
Calcium (mg)	490.0 ± 165.6	569.3 ± 205.3	443.9 ± 201.2	638.6 ± 268.1	470.7 ± 145.0	469. ± 271.2
Phosphorus (mg)	984.2 ± 276.7	1021.7 ± 198.3	1026.8 ± 160.4	926.5 ± 200.2	1003.4 ± 189.6	1065.8 ± 222.7
Potassium (mEq)	52.8 ± 19.1	53.0 ± 9.4	53.8 ± 11.4	45.5 ± 9.4	46.9 ± 8.9	53.4 ± 12.3

^a vs. T1 $p < 0.05$; ^b vs. T2 $p < 0.05$; ^c vs. T2 $p = 0.05$. ANOVA with Bonferroni post hoc for normally distributed data and Kruskal–Wallis for non-normally distributed data. BMI, body mass index; PNA, protein equivalent of nitrogen appearance; NaCl, sodium chloride.

BMD and biochemistry parameters are shown in Table 2. There were no statistical differences between the groups regarding BMD in the three sites (lumbar spine, femoral neck, and total femur). Phosphaturia was higher in T3 when compared to T1 and T2 among men and women. There was no statistical difference in both sexes regarding urinary oxalate, potassium, and eGFR.

Table 2. Biochemistry and BMD data of SFs clustered into tertiles according to urinary calcium.

	Men			Women		
	T1 n = 19 (≤180.0 mg/24 h)	T2 n = 20 (180.1–283.0 mg/24 h)	T3 n = 19 (≥283.1 mg/24 h)	T1 n = 16 (≤150 mg/24 h)	T2 n = 17 (150.1–289.0 mg/24 h)	T3 n = 16 (≥289.1 mg/24 h)
BMD parameters						
Lumbar spine BMD (g/cm ²)	0.99 ± 0.13	0.94 ± 0.08	1.04 ± 0.17	0.98 ± 0.03	0.94 ± 0.02	1.04 ± 0.04
Femoral neck BMD (g/cm ²)	0.83 ± 0.16	0.82 ± 0.11	0.93 ± 0.18	0.83 ± 0.04	0.82 ± 0.03	0.93 ± 0.04
Total femur BMD (g/cm ²)	0.97 ± 0.16	0.97 ± 0.12	1.06 ± 0.17	0.88 ± 0.10	0.88 ± 0.09	0.95 ± 0.14
Urinary parameters						
Calcium, mg/24 h	135.9 ± 29.6	236.9 ± 31.1 ^a	363.4 ± 80.0 ^{ab}	115.6 ± 26.8	217.6 ± 44.0 ^a	341.6 ± 58.2 ^{ab}
Oxalate, mg/24 h	22.2 ± 9.6	26.9 ± 8.4	28.6 ± 8.8	19.7 ± 7.0	20.0 ± 5.2	22.9 ± 7.5
Phosphate, mg/24 h	853.1 ± 268.6	963.8 ± 283.0	1204.8 ± 303.7 ^{ab}	593.9 ± 203.0	707.7 ± 127.8	886.6 ± 228.9 ^{ab}
Sodium, mEq/24 h	220.2 ± 74.8	237.2 ± 94.9	262.8 ± 90.0	166.8 ± 71.2	178.2 ± 50.3	239.3 ± 76.6 ^{ab}
Potassium, mg/24 h	56.4 ± 22.4	65.2 ± 22.3	62.2 ± 25.6	44.7 ± 16.3	47.7 ± 12.7	51.7 ± 12.4
eGFR, ml/min/1.73 m ²	97.3 ± 19.0	98.7 ± 15.5	96.3 ± 15.0	103.7 ± 13.3	102.4 ± 11.2	101.3 ± 10.9
Serum parameters						
Sclerostin (pmol/L)	21.4 (18.3–26.7)	28.8 (19.0–40.9) ^a	30.9 (25.4–37.1) ^{ab}	19.8 (11.0–23.9)	20.5 (17.5–23.0)	25.9 (17.5–29.4) ^c
25 Vitamin D, ng/mL	24.0 (20.0–29.0)	23.5 (20.8–30.3)	25.5 (19.8–29.3)	27.5 (21.0–35.0)	25.0 (22.0–29.0)	26.0 (21.0–34.0)
1–25 Vitamin D, pg/mL	30.7 (17.3–39.5)	22.0 (16.6–50.8)	26.4 (18.0–34.6)	20.9 (17.8–27.2)	20.4 (15.1–33.0)	28.6 (21.1–60.5)
PTH, pg/mL	53.0 (40.0–67.0)	52.0 (37.5–64.0)	59.0 (42.3–76.5)	50.0 (45.0–60.0)	44.0 (41.0–65.5)	52.5 (35.5–65.0)
BAP, U/L	16.4 ± 5.8	16.5 ± 4.7	16.2 ± 4.1	13.0 ± 2.7	13.6 ± 4.7	13.3 ± 3.1
FGF-23, pg/mL	34.3 (31.5–42.1)	34.2 (26.6–47.9)	33.1 (26.4–39.8)	31.2 (24.8–39.3)	28.3 (24.7–36.3)	34.4 (19.7–44.4)
Klotho, pg/mL	684.0 (520.0–974.0)	730.0 (518.3–801.7)	714.0 (570.7–870.7)	615.4 (438.2–888.5)	829.5 (569.7–1221.3)	875.7 (508.2–1247.7)

^a vs. T1 $p < 0.05$; ^b vs. T2 $p < 0.05$; ^c vs. T1 $p = 0.06$. ANOVA with Bonferroni post hoc for normally distributed data and Kruskal–Wallis for non-normally distributed data. BMD, bone mineral density; eGFR, estimate glomerular filtration rate; PTH, parathyroid hormone; BAP, bone alkaline phosphatase; FGF-23, fibroblast growth factor 23.

Regarding serum parameters, circulating sclerostin levels were higher among men in T3 compared to T1 and T2 (30.9 pmol/L [25.4–37.1] vs. 21.4 pmol/L [18.3–26.7] and 28.8 pmol/L [19.0–40.9], $p < 0.001$, respectively). Among women, T3 presented a trend for

higher serum sclerostin versus T1 (25.9 [17.5–29.4] vs. 19.8 [11.0–23.9], $p = 0.06$). There were no statistical differences between groups in both sexes regarding 25(OH)D₃, 1,25(OH)₂D₃, PTH, BAP, FGF-23, and klotho serum levels.

To correct for the influence of the weight load on bone, the lumbar spine BMD, femoral neck BMD, and total femur BMD were corrected for BMI by calculating their ratios, the mean values of which were 0.037 ± 0.006 , 0.030 ± 0.006 , and 0.036 ± 0.006 , respectively (data not shown in tables).

We subsequently performed linear regression to investigate possible clinical, laboratory, and dietary factors as determinants of urinary calcium. Associations were explored for already established factors that influence urinary calcium. The linear regression analysis results are presented in Table 3. Upon univariate analysis, we observed significant positive associations between urinary calcium and age (st. β 0.26, $p < 0.01$), presence of hypertension (st. β 0.33, $p < 0.01$), NaCl intake (st. β 0.31, $p < 0.01$), serum sclerostin (st. β 0.31, $p < 0.01$), and a negative association with the lumbar spine BMD/BMI ratio (st. β -0.24 , $p = 0.02$). In multivariate linear regression analyses, the presence of hypertension, NaCl intake, and serum sclerostin remained strongly associated with urinary calcium (st. β 0.30, $p < 0.01$; st. β 0.31, $p = 0.02$; st. β 0.26, $p = 0.01$, respectively).

Table 3. Potential determinants of urinary calcium.

Potential Determinants	Total			
	Univariate		Multivariate *	
	St. β	p	St. β	p
Age, years	0.26	<0.01	-	-
Sex, F	-0.11	0.25	-	-
Hypertension, yes	0.33	<0.01	0.30	<0.01
Fat mass, %	0.07	0.46	-	-
Lean mass, %	-0.08	0.41	-	-
NaCl intake, g/day	0.31	<0.01	0.31	0.02
PNA, g/kg/day	0.01	0.95	-	-
Calcium intake, mg/day	-0.19	0.11	-	-
Serum sclerostin, pmol/L	0.31	<0.01	0.26	0.01
Serum 1–25 vitamin D, pg/mL	0.02	0.87	-	-
Serum PTH, pg/mL	-0.05	0.62	-	-
Serum BAP, U/L	0.04	0.72	-	-
FGF-23, pg/mL	-0.08	0.43	-	-
Lumbar spine BMD/BMI ratio	-0.24	0.02	-	-
Femoral neck BMD/BMI ratio	-0.13	0.19	-	-
Total femur BMD/BMI ratio	-0.18	0.06	-	-

Linear regression analysis with serum sclerostin as dependent variable. * Run backwards, variables with $p < 0.10$ in univariate analysis included. Abbreviations: St. β , standardized beta; NaCl, sodium chloride; PNA, protein equivalent of total nitrogen appearance; PTH, parathyroid hormone; BAP, bone alkaline phosphatase; FGF-23, fibroblast growth factor 23.

In the current study, circulating sclerostin was associated with body composition among male SFs. As shown in Figure 1, serum sclerostin levels were positively associated with fat mass % among men (β 0.38, $p = 0.004$), but not in women (β 0.22, $p = 0.14$). Further, it was negatively associated with body lean mass % among men (β -0.32 , $p = 0.01$), but not among women (β -0.20 , $p = 0.17$).




Figure 1. Association scatterplots of serum sclerostin levels with fat mass % (Men: β 0.38, $p = 0.004$; Women: β 0.22, $p = 0.14$) and lean mass % (Men: β -0.32 , $p = 0.01$; Women: β -0.20 , $p = 0.17$).

4. Discussion

In the present study, both male and female stone formers with higher urinary calcium excretion exhibited higher prevalence of hypertension, metabolic syndrome, and higher BMI. Among male SFs, a significantly higher fat mass % and lower lean mass % were evidenced in parallel with increased calciuria and circulating levels of sclerostin. A trend for higher serum sclerostin was also disclosed in female SFs with more elevated urinary calcium levels. Notably, serum sclerostin levels, hypertension, and salt intake were shown to be independent determinants of urinary calcium.

The present association of BMI with urinary calcium agrees well with previous findings of a larger cohort from our group showing correlations with waist circumference as well [5] and with data reported by Shavit et al. [20], which emphasized that obese and overweight SFs patients have higher urinary calcium.

There was a higher prevalence of hypertensive patients in the highest tertile of calciuria in both sexes in the current study, with hypertension ending up as an independent determinant of urinary calcium in a multivariate linear regression. Hypertension has already been associated with abnormalities in calcium metabolism and renal tubular calcium handling resulting in an increased urinary calcium [21].

The current independent and positive association of NaCl intake with urinary calcium levels is in line with previous studies [22]. This effect is attributed to the complex interplay between sodium and calcium transport mechanisms in the kidneys. A high sodium diet suppresses both proximal sodium and calcium reabsorption increasing the delivery of cal-

cium to the distal nephron, exceeding its transport capacity, resulting in hypercalciuria [23]. In addition, prolonged exposure to high dietary NaCl may have implications for bone loss in stone formers as well. [24].

In the present series, circulating sclerostin levels were higher among patients in the highest tertiles of urinary calcium (tertiles 2 and 3). A trend for higher level of sclerostin among female SFs was found in the T3 of urinary calcium ($p = 0.06$). In addition, the multivariate regression analysis disclosed circulating sclerostin as a strong determinant of urinary calcium, even when adjusting for sex (β 0.30, $p < 0.01$). The way by which sclerostin may influence calcium reabsorption in the distal tubule has been investigated in an elegant experimental study by Ryan et al. [17] who showed that *Sost* KO mice had lower urinary calcium, increased serum levels of $1,25(\text{OH})_2\text{D}_3$ and phosphorus, and decreased FGF-23, which may have contributed to the regulation of mineral accretion, resulting in increased BMD observed in these animals. Sclerostin indirect effects on calciuria could be mediated by the inhibition of CYP27B1 expression leading to the lower synthesis of $1,25(\text{OH})_2\text{D}_3$ or by the stimulation of the release of FGF-23 in bone, which in turn would inhibit the renal production of $1,25(\text{OH})_2\text{D}_3$ [18]. The FGF-23 concentration was indeed diminished in *Sost* KO mice along with an increase in serum phosphate concentrations [17]. Since $1,25(\text{OH})_2\text{D}_3$ stimulates Ca reabsorption at distal tubule, the inhibitory effects of its synthesis are expected to favor Ca excretion. Interestingly, PTH appears to inhibit sclerostin concentrations, as evidenced by its effects decreasing *Sost* expression in primary cultures of murine calvaria cells [25] as a hormonal control of osteoblastogenesis. However, we have not observed significant differences among $1,25(\text{OH})_2\text{D}_3$, FGF-23, or PTH levels across tertiles of calciuria in the current series. Moreover, a former study by our group showed increased serum $1,25(\text{OH})_2\text{D}_3$ (within normality range) and monocyte expression of the vitamin D receptor (VDR) in SFs when compared to healthy subjects, irrespective of their values of urinary calcium [26]. On the other hand, in a previous immunohistochemical analysis of bone tissue from hypercalciuric SFs conducted by our group, Menon et al. [9] showed a significant positive correlation between sclerostin immunostaining in bone with serum $1,25(\text{OH})_2\text{D}_3$ in idiopathic hypercalciuric patients, which is in accordance with previous experimental data [27]. Therefore, it is possible that the tubular effects of sclerostin on the tubule are direct and not through any of the abovementioned mechanisms.

Regarding body composition, the current findings of a direct correlation of fat mass and inverse correlation of lean mass with serum sclerostin only among men agree well with previous studies [14,15], albeit this has been observed in women [28]. The negative association between sclerostin and muscle mass can be explained, at least in part, by an experimental study showing that older *Sost* KO mice exhibited the expected increases in bone mass but a significant reduction in whole-body fat mass and a strong trend toward increased lean body mass fraction [16].

Finally, the present data did not show differences in BMD according to tertiles of calciuria in both sexes. Despite the well-known association of low BMD with hypercalciuria, as suggested by most studies [6,10,29], it still remains a controversial matter as many investigators have reported low BMD among normocalciuric individuals as well [12], which is in agreement with the present findings of a lack of differences in BMD according to the levels of calciuria. In a very recent cross-sectional study of our group employing HRpQCT in SFs, Esper et al. [11] observed a reduced trabecular number (Tb.N) and volumetric BMD, indicating trabecular bone microarchitecture impairment, especially among women, as well as reduced bone strength parameters in men. Interestingly, they observed through a multivariate analysis an independent association of Tb.N with urinary calcium only at the distal radius, although BMI was a strong predictor of Tb.N at both radius and tibia. Such findings suggest that the mechanical loading to the tibia bones might have counteracted the calciuric effect at this site. Therefore, we considered the BMD/BMI ratio to be more adequate for comparisons with urinary calcium. However, although we observed a significant inverse association between the lumbar spine BMD/BMI ratio ($p = 0.02$, Table 3) with urinary calcium and a trend for the same association in total femur

site ($p = 0.06$, Table 3) in univariate analysis, these two variables did not remain in the multivariate model. Interestingly, the use of a monoclonal antibody against sclerostin in healthy postmenopausal women has induced a dose-related reduction in mean urinary calcium levels [30].

Nevertheless, our study has some limitations. First, due to the cross-sectional nature of our study sample, it is not possible to prove causalities. This is a single-center-designed study, and thus the results could not be generalized to the overall population. Also, the present sample is relatively small. On the other hand, to the best of our knowledge, this is the first study to disclose an association of sclerostin and urinary calcium in stone formers.

In conclusion, in addition to hypertension and elevated salt intake, circulating sclerostin was shown to be a strong and independent determinant of urinary calcium among stone-forming patients. Moreover, sclerostin was correlated with body composition. These data suggest that in addition to the hormones traditionally thought to alter calcium reabsorption in the kidney, sclerostin may play a significant additional role, possibly intermediated by body composition, warranting further intervention studies in order to test potential medication strategies to reduce calciuria in this population.

Author Contributions: Conceptualization: F.G.R. and I.P.H.; methodology: F.G.R. and M.S.O.; formal analysis and investigation: F.G.R.; writing—original draft preparation: F.G.R.; writing—review and editing: F.G.R., I.P.H., M.H.D.B., A.C.C.d.M. and I.G.P.; supervision: I.P.H. and M.H.D.B. All authors have read and agreed to the published version of the manuscript.

Funding: This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES).

Institutional Review Board Statement: Study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed Consent Statement: Written consent was obtained from each patient, and the study protocol was approved by the local Medical Ethics and Research Committee of UNIFESP (number 4.869.310).

Data Availability Statement: The data that support the findings of this study are available from the corresponding author, upon reasonable request.

Conflicts of Interest: The authors have no relevant financial or non-financial interest to disclose.

References

1. Coe, F.L.; Worcester, E.M.; Evan, A.P. Idiopathic Hypercalciuria and Formation of Calcium Renal Stones. *Nat. Rev. Nephrol.* **2016**, *12*, 519–533. [[CrossRef](#)] [[PubMed](#)]
2. Gambaro, G.; Croppi, E.; Coe, F.; Lingeman, J.; Moe, O.; Worcester, E.; Buchholz, N.; Bushinsky, D.; Curhan, G.C.; Ferraro, P.M.; et al. Metabolic Diagnosis and Medical Prevention of Calcium Nephrolithiasis and Its Systemic Manifestations: A Consensus Statement. *J. Nephrol.* **2016**, *29*, 715–734. [[CrossRef](#)]
3. Figueres, L.; Hourmant, M.; Lemoine, S. Understanding and Managing Hypercalciuria in Adults with Nephrolithiasis: Keys for Nephrologists. *Nephrol. Dial. Transplant.* **2020**, *35*, 573–575. [[CrossRef](#)] [[PubMed](#)]
4. Powell, C.R.; Stoller, M.L.; Schwartz, B.F.; Kane, C.; Gentle, D.L.; Bruce, J.E.; Leslie, S.W. Impact of Body Weight on Urinary Electrolytes in Urinary Stone Formers. *Urology* **2000**, *55*, 825–830. [[CrossRef](#)] [[PubMed](#)]
5. Rodrigues, F.G.; Lima, T.M.; Zambrano, L.; Heilberg, I.P. Dietary Pattern Analysis among Stone Formers: Resemblance to a DASH-Style Diet. *Braz. J. Nephrol.* **2020**, *42*, 338–348. [[CrossRef](#)] [[PubMed](#)]
6. Heilberg, I.P.; Weisinger, J.R. Bone Disease in Idiopathic Hypercalciuria. *Curr. Opin. Nephrol. Hypertens.* **2006**, *15*, 394–402. [[CrossRef](#)]
7. Heilberg, I.P.; Carvalho, A.B. Bone Histopathology and Disease in Hypercalciuria. In *Kidney Stones: Medical and Surgical Management*; Coe, F., Worcester, E., Lingeman, J., Evan, A., Eds.; Jaypee Brothers Medical Publishers: London, UK, 2019; pp. 303–320.
8. Gomes, S.A.; dos Reis, L.M.; Noronha, I.L.; Jorgetti, V.; Heilberg, I.P. RANKL Is a Mediator of Bone Resorption in Idiopathic Hypercalciuria. *Clin. J. Am. Soc. Nephrol.* **2008**, *3*, 1446–1452. [[CrossRef](#)]
9. Menon, V.B.; Moysés, R.M.; Gomes, S.A.; de Carvalho, A.B.; Jorgetti, V.; Heilberg, I.P. Expression of Fibroblast Growth Factor 23, Vitamin D Receptor, and Sclerostin in Bone Tissue from Hypercalciuric Stone Formers. *Clin. J. Am. Soc. Nephrol.* **2014**, *9*, 1263–1270. [[CrossRef](#)]

10. Asplin, J.R.; Donahue, S.; Kinder, J.; Coe, F.L. Urine Calcium Excretion Predicts Bone Loss in Idiopathic Hypercalciuria. *Kidney Int.* **2006**, *70*, 1463–1467. [[CrossRef](#)]
11. Esper, P.L.G.; Rodrigues, F.G.; Melo, T.L.; Ormanji, M.S.; Campos, C.M.; Alvarenga, J.C.; Caparbo, V.D.F.; Carvalho, A.B.; Pereira, R.M.R.; Heilberg, I.P. Bone Density, Microarchitecture, and Estimated Strength in Stone Formers: A Cross-Sectional HR-PQCT Study. *Nephrol. Dial. Transplant.* **2022**, *38*, 425–434. [[CrossRef](#)]
12. Sakhaee, K.; Maalouf, N.M.; Poindexter, J.; Adams-Huet, B.; Moe, O.W. Relationship between Urinary Calcium and Bone Mineral Density in Patients with Calcium Nephrolithiasis. *J. Urol.* **2017**, *197*, 1472–1477. [[CrossRef](#)]
13. Van Bezooijen, R.L.; Roelen, B.A.; Visser, A.; van der Wee-Pals, L.; de Wilt, E.; Karperien, M.; Hamersma, H.; Papapoulos, S.E.; ten Dijke, P.; Löwik, C.W. Sclerostin Is an Osteocyte-Expressed Negative Regulator of Bone Formation, but Not a Classical BMP Antagonist. *J. Exp. Med.* **2004**, *199*, 805–814. [[CrossRef](#)] [[PubMed](#)]
14. Ma, Y.H.; Schwartz, A.V.; Sigurdsson, S.; Hue, T.F.; Lang, T.F.; Harris, T.B.; Rosen, C.J.; Vittinghoff, E.; Eiriksdottir, G.; Hauksdottir, A.M.; et al. Circulating Sclerostin Associated with Vertebral Bone Marrow Fat in Older Men but Not Women. *J. Clin. Endocrinol. Metab.* **2014**, *99*, E2584–E2590. [[CrossRef](#)] [[PubMed](#)]
15. Amrein, K.; Amrein, S.; Drexler, C.; Dimai, H.P.; Dobnig, H.; Pfeifer, K.; Tomaschitz, A.; Pieber, T.R.; Fahrleitner-Pammer, A. Sclerostin and Its Association with Physical Activity, Age, Gender, Body Composition, and Bone Mineral Content in Healthy Adults. *J. Clin. Endocrinol. Metab.* **2012**, *97*, 148–154. [[CrossRef](#)] [[PubMed](#)]
16. Kim, S.P.; Frey, J.L.; Li, Z.; Kushwaha, P.; Zoch, M.L.; Tomlinson, R.E.; Da, H.; Aja, S.; Noh, H.L.; Kim, J.K.; et al. Sclerostin Influences Body Composition by Regulating Catabolic and Anabolic Metabolism in Adipocytes. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, E11238–E11247. [[CrossRef](#)]
17. Ryan, Z.C.; Ketha, H.; McNulty, M.S.; McGee-Lawrence, M.; Craig, T.A.; Grande, J.P.; Westendorf, J.J.; Singh, R.J.; Kumar, R. Sclerostin Alters Serum Vitamin D Metabolite and Fibroblast Growth Factor 23 Concentrations and the Urinary Excretion of Calcium. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 6199–6204. [[CrossRef](#)]
18. Kumar, R.; Vallon, V. Reduced Renal Calcium Excretion in the Absence of Sclerostin Expression: Evidence for a Novel Calcium-Regulating Bone Kidney Axis. *J. Am. Soc. Nephrol.* **2014**, *25*, 2159–2168. [[CrossRef](#)]
19. Tozzi, R.; Masi, D.; Cipriani, F.; Contini, S.; Gangitano, E.; Spoltore, M.E.; Barchetta, I.; Basciani, S.; Watanabe, M.; Baldini, E.; et al. Circulating SIRT1 and Sclerostin Correlates with Bone Status in Young Women with Different Degrees of Adiposity. *Nutrients* **2022**, *14*, 983. [[CrossRef](#)]
20. Shavit, L.; Ferraro, P.M.; Johri, N.; Robertson, W.; Walsh, S.B.; Moochhala, S.; Unwin, R. Effect of Being Overweight on Urinary Metabolic Risk Factors for Kidney Stone Formation. *Nephrol. Dial. Transplant.* **2015**, *30*, 607–613. [[CrossRef](#)]
21. Mente, A.; Honey, R.J.D.A.; McLaughlin, J.M.; Bull, S.B.; Logan, A.G. High Urinary Calcium Excretion and Genetic Susceptibility to Hypertension and Kidney Stone Disease. *J. Am. Soc. Nephrol.* **2006**, *17*, 2567–2575. [[CrossRef](#)]
22. Park, S.M.; Jee, J.; Joung, J.Y.; Cho, Y.Y.; Sohn, S.Y.; Jin, S.M.; Hur, K.Y.; Kim, J.H.; Kim, S.W.; Chung, J.H.; et al. High Dietary Sodium Intake Assessed by 24-Hour Urine Specimen Increase Urinary Calcium Excretion and Bone Resorption Marker. *J. Bone Miner. Res.* **2014**, *29*, 189–194. [[CrossRef](#)] [[PubMed](#)]
23. Moe, O.W.; Preisig, P.A.; Pak, J. *Hypothesizing on the Evolutionary Origins of Salt-Induced Hypercalciuria*; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2005; Volume 14.
24. Martini, L.A.; Cuppari, L.; Colugnati, F.A.; Sigulem, D.M.; Szejnfeld, V.L.; Schor, N.; Heilberg, I.P. High Sodium Chloride Intake Is Associated with Low Bone Density in Calcium Stone-Forming Patients. *Clin. Nephrol.* **2000**, *54*, 85–93.
25. Bellido, T.; Ali, A.A.; Gubrij, I.; Plotkin, L.I.; Fu, Q.; O'Brien, C.A.; Manolagas, S.C.; Jilka, R.L. Chronic Elevation of Parathyroid Hormone in Mice Reduces Expression of Sclerostin by Osteocytes: A Novel Mechanism for Hormonal Control of Osteoblastogenesis. *Endocrinology* **2005**, *146*, 4577–4583. [[CrossRef](#)] [[PubMed](#)]
26. Melo, T.L.; Esper, P.L.G.; Zambrano, L.I.; Ormanji, M.S.; Rodrigues, F.G.; Heilberg, I.P. Expression of Vitamin D Receptor, CYP27B1 and CYP24A1 Hydroxylases and 1,25-Dihydroxyvitamin D Levels in Stone Formers. *Urolithiasis* **2020**, *48*, 19–26. [[CrossRef](#)] [[PubMed](#)]
27. Wijenayaka, A.R.; Yang, D.; Prideaux, M.; Ito, N.; Kogawa, M.; Anderson, P.H.; Morris, H.A.; Solomon, L.B.; Loots, G.G.; Findlay, D.M.; et al. 1 α ,25-Dihydroxyvitamin D₃ Stimulates Human SOST Gene Expression and Sclerostin Secretion. *Mol. Cell Endocrinol.* **2015**, *413*, 157–167. [[CrossRef](#)]
28. Ardawi, M.-S.M.; Al-Kadi, H.A.; Rouzi, A.A.; Qari, M.H. Determinants of Serum Sclerostin in Healthy Pre- and Postmenopausal Women. *J. Bone Miner. Res.* **2011**, *26*, 2812–2822. [[CrossRef](#)]
29. Vezzoli, G.; Rubinacci, A.; Bianchin, C.; Arcidiacono, T.; Giambona, S.; Mignogna, G.; Fochesato, E.; Terranegra, A.; Cusi, D.; Soldati, L. Intestinal Calcium Absorption Is Associated with Bone Mass in Stone-Forming Women with Idiopathic Hypercalciuria. *Am. J. Kidney Dis.* **2003**, *42*, 1177–1183. [[CrossRef](#)]
30. Mccolm, J.; Hu, L.; Womack, T.; Tang, C.C.; Chiang, A.Y. Single- and Multiple-Dose Randomized Studies of Blosozumab, a Monoclonal Antibody against Sclerostin, in Healthy Postmenopausal Women. *J. Bone Miner. Res.* **2014**, *29*, 935–943. [[CrossRef](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.